New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies »

[at noodls] – Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS Gilenya is the first oral disease … more

View todays social media effects on NVS

View the latest stocks trending across Twitter. Click to view dashboard

See who Novartis is hiring next, click here to view